# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mumtaz Mahal (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE006-SYN
- Date: 2026-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Farzana Qureshi-Lindholm, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Prenatal visit at 27 weeks. **S**

## History of present illness

Mumtaz Mahal returns at 27 weeks 2 days. The cystitis three weeks ago settled within two days of starting nitrofurantoin, and the culture grew Escherichia coli sensitive to it; she finished the 5-day course. She has no urinary symptoms now. She feels well, with good energy, and the baby moves often. She takes aspirin and folic acid. She has no headache, visual change, swelling of the face or hands, abdominal pain, contractions, bleeding, or leaking fluid. Her family plans to travel for about six weeks, starting next week, mostly by road, and she intends to go with them. **S**

| Element | Detail |
|---|---|
| Cystitis | Resolved; culture Escherichia coli, sensitive to nitrofurantoin; course completed |
| Energy | Good since the second iron dose |
| Fetal movement | Frequent |
| Travel | About six weeks of road travel planned from next week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Well; energy good |
| Cardiovascular | Negative | No breathlessness, palpitations, or leg swelling |
| Neurological | Negative | No headache or visual change |
| Genitourinary | Negative | No urinary symptoms, bleeding, or leaking fluid |
| Psychiatric | Negative | Mood steady; EPDS 6 |

5 systems reviewed. **S**

## Current medications

- Folic acid 0.4 mg oral tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 86 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 64.6 kg; BMI 26.2 kg/m². All vital signs are synthetic.

Hemoglobin: 11.4 g/dL; Ferritin: 110 ng/mL; Platelets: 232 10*3/uL; 1-hour glucose challenge: 128 mg/dL; EPDS: 6. All results are synthetic.

## Change since baseline

- Hemoglobin: 10.1 g/dL (low) at baseline, 11.4 g/dL at this visit **S**
- Ferritin: 9 ng/mL (low) at baseline, 110 ng/mL at this visit **S**
- Platelets: 245 10*3/uL at baseline, 232 10*3/uL at this visit **S**
- EPDS: 8 at baseline, 6 at this visit **S**

## Immunizations given today

- Tdap vaccine in pregnancy, 27 weeks **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Abdomen | Fundal height 27 cm; non-tender |
| Fetal | Fetal heart 144 per minute by Doppler |
| Extremities | No edema; calves soft and non-tender |
| Urine dipstick | Protein negative; leukocytes and nitrite negative |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Acute cystitis in pregnancy** (O23.12). Resolved after nitrofurantoin. **S**
   - Test-of-cure urine culture sent today.
2. **Iron deficiency anemia in pregnancy** (O99.019). Hemoglobin 11.4 g/dL and ferritin 110 ng/mL: anemia corrected and iron replete after two intravenous doses. **S**
   - Repeat blood count at the next visit.
3. **Fourteenth pregnancy at 37** (O09.529). One-hour glucose challenge 128 mg/dL, below 140: no gestational diabetes. Platelets 232. Blood pressure 108/68 mmHg. Fundal height 27 cm, consistent with dates. EPDS 6 with item 10 scored 0. She is RhD positive, so no anti-D is needed. **S**
   - Tdap given today.
   - Start daily fetal movement awareness from 28 weeks.
   - Visits every two weeks from 28 weeks; growth scan at about 32 to 34 weeks.
4. **Grand multiparity and travel** (O09.40). Travel is reasonable now if she stays well, but she must not miss third-trimester checks, and her labors have been short. **S**
   - Copy of her prenatal record and scan reports given.
   - Arrange prenatal visits where she stays, at 30 and 32 weeks, and return before 34 to 36 weeks to stay near the delivery hospital.
   - On long journeys: stop to walk every one to two hours, drink plenty, wear compression stockings, and wear the seat belt below the bump.
   - Seek care at once for headache, visual change, abdominal pain, bleeding, leaking fluid, regular contractions, reduced movements, or a painful swollen leg.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 108/68 mmHg; urine protein negative |
| Examination | Fetal heart and fundal height | Every prenatal visit | Completed today | Fetal heart 144 per minute; fundal height 27 cm |
| Examination | Weight gain | Every prenatal visit | Completed today | 64.6 kg, up 6.0 kg since intake |
| Laboratory | Hemoglobin and ferritin | At intake, four weeks after starting treatment, at 24 to 28 weeks, and before delivery | Completed today | Hemoglobin 11.4 g/dL and ferritin 110 ng/mL |
| Laboratory | Gestational diabetes screen (one-hour 50 g glucose challenge) | At 24 to 28 weeks | Completed today | 128 mg/dL, below the 140 mg/dL threshold |
| Laboratory | Urine culture as a test of cure after cystitis | One to two weeks after treatment | Ordered | Sent today, two weeks after the course ended |
| Laboratory | Antibody screen and anti-D at 28 weeks | At 28 weeks for RhD-negative patients | Not indicated | RhD positive with a negative antibody screen at intake |
| Medication safety | Tdap vaccine | Once at 27 to 36 weeks in every pregnancy | Completed today | Given today |
| Medication safety | Low-dose aspirin | Daily from 12 to 16 weeks until delivery; review at every visit | Completed today | Taken nightly; no bruising or bleeding |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Completed today | 6; item 10 scored 0 |
| Self-management | Travel planning | Before any travel in pregnancy | Completed today | Six weeks of road travel planned; records given; care to be arranged where she stays |
| Self-management | Postpartum hemorrhage risk assessment and birth plan | At intake, in the third trimester, and on admission for birth | Up to date | Anemia corrected; grand multiparity remains; detailed plan at the next visit |

## Goal progress

- Hemoglobin at least 11 g/dL with replete iron stores before delivery. In progress; target 2026-06-02. **S**
- An informed choice about aneuploidy screening by 14 weeks. Outcome by 2026-02-03: Chose cell-free DNA (low risk) with the nuchal translucency scan (1.7 mm); declined diagnostic testing. **S**
- Blood pressure below 140/90 mmHg with aspirin taken nightly from 13 weeks. In progress; target 2026-07-12. **S**
- A written delivery and postpartum hemorrhage plan agreed by 36 weeks, with birth planned in a hospital with a blood bank and operating theatre. In progress; target 2026-06-02. **S**
- A postpartum contraception choice and a plan for the interval before any future pregnancy, made on her own terms before delivery. In progress; target 2026-06-02. **S**

## Guideline basis

- Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)
- Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021), U.S. Preventive Services Task Force
- ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus (2018), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- ACOG Committee Opinion No. 746: Air Travel During Pregnancy (2018), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America (2019), Infectious Diseases Society of America (Clinical Infectious Diseases)

## Follow-up

- Prenatal visits at 30 and 32 weeks where she is staying, then here on her return. **S**
- Next scheduled visit 2026-06-02: prenatal visit at 34 weeks: growth scan, postpartum hemorrhage risk assessment, delivery plan, and contraception counseling. **S**
